MLYS logo

MLYS
Mineralys Therapeutics Inc

603
Mkt Cap
$2.46B
Volume
786,960.00
52W High
$47.65
52W Low
$12.59
PE Ratio
-14.49
MLYS Fundamentals
Price
$29.85
Prev Close
$30.23
Open
$30.47
50D MA
$27.24
Beta
1.03
Avg. Volume
1.11M
EPS (Annual)
-$2.29
P/B
3.86
Rev/Employee
$0.00
$1,798.61
Loading...
Loading...
News
all
press releases
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Rating of "Moderate Buy" by Brokerages
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rat...
News Placeholder
More News
News Placeholder
Mineralys Therapeutics (MLYS) Projected to Post Earnings on Wednesday
Mineralys Therapeutics (NASDAQ:MLYS) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-mineralys-therapeutics-inc-stock...
News Placeholder
Mineralys Therapeutics (NASDAQ:MLYS) Trading 8.2% Higher - Should You Buy?
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 8.2% - Should You Buy...
News Placeholder
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Jennison Associates LLC
Jennison Associates LLC grew its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 234.4% in the fourth quarter, according to its most recent filing with the...
News Placeholder
Pictet Asset Management Holding SA Sells 76,286 Shares of Mineralys Therapeutics, Inc. $MLYS
Pictet Asset Management Holding SA trimmed its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 8.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 852,883 shares of the...
News Placeholder
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's Why
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's What Happened...
News Placeholder
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 416 Shares of Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 416 shares of the business's stock in a transaction that occurred on Friday, April 17th. The shares were...
News Placeholder
David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 416 shares of the stock in a transaction dated Friday, April 17th. The stock was sold at an average price...
News Placeholder
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock in a transaction dated Wednesday, April 15th. The shares...
News Placeholder
Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $422,035.90 in Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CEO Jon Congleton sold 15,730 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, April 13th. The stock was...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available